Remove Contract Manufacturing Remove Immune Response Remove In-Vivo Remove Licensing
article thumbnail

The challenges and trends of cell & gene therapies 

Drug Discovery World

Speaking about emerging opportunities, Carlo Russo, CEO of Genenta, says that whilst “immuno-oncology treatment has been very successful in treating patients suffering from blood cancer,” its success has been limited “by the durability of the responses”. billion, compared to $19.9 million price point per dose.